Article
Genentech Presents New Data From Multiple Phase III Studies of Tecentriq in Triple-Negative Breast
Rating:
0.0
Views:
34
Likes:
1
Library:
1
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that it presented the latest results from three Phase III studies
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value